Benign and Malignant Diseases of the Prostate

  • Jamil SyedEmail author
  • Preston Sprenkle
Living reference work entry


A significant number of people will experience urologic disease with age. The breath of urology covers the entire urinary tract along with the retroperitoneum and male genital structures. Herein, we discuss diseases of the kidney, bladder, and prostate with a particular focus in malignancies of these organ systems.


  1. 1.
    Berry SJ, Coffey DS, Walsh PC, Ewing LL (1984) The development of human benign prostatic hyperplasia with age. J Urol 132:474–479CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Jacobsen SJ, Jacobson DJ, Girman CJ et al (1999) Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status. J Urol 162:1301–1306PubMedCrossRefGoogle Scholar
  3. 3.
    Ketchandji M, Kuo YF, Shahinian VB, Goodwin JS (2009) Cause of death in older men after the diagnosis of prostate cancer. J Am Geriatr Soc 57:24–30PubMedCrossRefGoogle Scholar
  4. 4.
    Taylor JA 3rd, Kuchel GA (2006) Detrusor underactivity: clinical features and pathogenesis of an underdiagnosed geriatric condition. J Am Geriatr Soc 54:1920–1932PubMedCrossRefGoogle Scholar
  5. 5.
    Roberts RO, Bergstralh EJ, Cunningham JM et al (2004) Androgen receptor gene polymorphisms and increased risk of urologic measures of benign prostatic hyperplasia. Am J Epidemiol 159:269–276PubMedCrossRefGoogle Scholar
  6. 6.
    Elbadawi A, Yalla SV, Resnick NM (1993) Structural basis of geriatric voiding dysfunction. I. Methods of a prospective ultrastructural/urodynamic study and an overview of the findings. J Urol 150:1650–1656PubMedCrossRefGoogle Scholar
  7. 7.
    Malone-Lee J, Wahedna I (1993) Characterisation of detrusor contractile function in relation to old age. Br J Urol 72:873–880PubMedCrossRefGoogle Scholar
  8. 8.
    Resnick NM, Yalla SV (1987) Detrusor hyperactivity with impaired contractile function. An unrecognized but common cause of incontinence in elderly patients. JAMA 257:3076–3081PubMedCrossRefGoogle Scholar
  9. 9.
    Resnick NM, Yalla SV, Laurino E (1989) The pathophysiology of urinary incontinence among institutionalized elderly persons. N Engl J Med 320:1–7PubMedCrossRefGoogle Scholar
  10. 10.
    Chaikin DC, Blaivas JG (2001) Voiding dysfunction: definitions. Curr Opin Urol 11:395–398PubMedCrossRefGoogle Scholar
  11. 11.
    Su L, Guess HA, Girman CJ et al (1996) Adverse effects of medications on urinary symptoms and flow rate: a community-based study. J Clin Epidemiol 49:483–487PubMedCrossRefGoogle Scholar
  12. 12.
    Davis R, Jones JS, Barocas DA, Castle EP et al (2012) Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. J Urol Suppl 188:2473CrossRefGoogle Scholar
  13. 13.
    Carroll PR, Parsons JK, Andriole G, Bahnson RR et al (2015) NCCN clinical practice guidelines prostate cancer early detection, version 2.2015. J Natl Compr Cancer Netw 13:1534CrossRefGoogle Scholar
  14. 14.
    Lepor H (1998) Phase III multicenter placebo-controlled study of Tamsulosin in benign prostatic hyperplasia. Urology 51:892–900PubMedCrossRefGoogle Scholar
  15. 15.
    Hellstrom WJ, Sikka SC (2006) Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers. J Urol 176:1529–1533PubMedCrossRefGoogle Scholar
  16. 16.
    Cantrell MA, Bream-Rouwenhorst HR, Steffensmeier A, Hemerson P, Rogers M, Stamper B (2008) Intraoperative floppy iris syndrome associated with alpha1-adrenergic receptor antagonists. Ann Pharmacother 42:558PubMedCrossRefGoogle Scholar
  17. 17.
    McConnell JD, Bruskewitz R, Walsh P et al (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 338:557–563PubMedCrossRefGoogle Scholar
  18. 18.
    Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG (1995) A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The veterans affairs cooperative study group on transurethral resection of the prostate. N Engl J Med 332:75–79PubMedCrossRefGoogle Scholar
  19. 19.
    Geavlete B, Stanescu F, Iacoboaie C, Geavlete P (2013) Bipolar plasma enucleation of the prostate vs open prostatectomy in large benign prostatic hyperplasia cases – a medium term, prospective, randomized comparison. BJU Int 111:793PubMedCrossRefGoogle Scholar
  20. 20.
    Miller KD, Nogueira L, Mariotto AB et al (2019) Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin 69:363–385PubMedCrossRefGoogle Scholar
  21. 21.
    Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69:7–34CrossRefGoogle Scholar
  22. 22.
    Edwards CN, Steinthorsson E, Nicholson D (1953) An autopsy study of latent prostatic cancer. Cancer 6:531–554PubMedCrossRefGoogle Scholar
  23. 23.
    Smith JR, Freije D, Carpten JD et al (1996) Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science (New York, NY) 274:1371–1374CrossRefGoogle Scholar
  24. 24.
    Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC (1990) Family history and the risk of prostate cancer. Prostate 17:337–347PubMedCrossRefGoogle Scholar
  25. 25.
    Draisma G, De Koning HJ (2003) MISCAN: estimating lead-time and over-detection by simulation. BJU Int 92(Suppl 2):106–111PubMedCrossRefGoogle Scholar
  26. 26.
    Byar DP, Mostofi FK (1972) Carcinoma of the prostate: prognostic evaluation of certain pathologic features in 208 radical prostatectomies. Examined by the step-section technique. Cancer 30:5–13PubMedCrossRefGoogle Scholar
  27. 27.
    McNeal JE (1992) Cancer volume and site of origin of adenocarcinoma in the prostate: relationship to local and distant spread. Hum Pathol 23:258–266PubMedCrossRefGoogle Scholar
  28. 28.
    Gilliland F, Becker TM, Smith A, Key CR, Samet JM (1994) Trends in prostate cancer incidence and mortality in New Mexico are consistent with an increase in effective screening. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive. Oncology 3:105–111Google Scholar
  29. 29.
    Ellis WJ, Chetner MP, Preston SD, Brawer MK (1994) Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography. J Urol 152:1520–1525PubMedCrossRefGoogle Scholar
  30. 30.
    Carter HB, Pearson JD, Metter EJ et al (1992) Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267:2215–2220PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Catalona WJ, Smith DS, Ratliff TL, Basler JW (1993) Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 270:948–954PubMedCrossRefGoogle Scholar
  32. 32.
    Albertsen PC, Hanley JA, Harlan LC et al (2000) The positive yield of imaging studies in the evaluation of men with newly diagnosed prostate cancer: a population based analysis. J Urol 163:1138–1143PubMedCrossRefGoogle Scholar
  33. 33.
    Siddiqui MM, Rais-Bahrami S, Turkbey B et al (2015) Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA 313:390–397PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Syed JS, Nguyen KA, Nawaf CB et al (2017) Prostate zonal anatomy correlates with the detection of prostate cancer on multiparametric magnetic resonance imaging/ultrasound fusion-targeted biopsy in patients with a solitary PI-RADS v2-scored lesion. Urol Oncol 35:542.e19–24CrossRefGoogle Scholar
  35. 35.
    Sheridan AD, Nath SK, Aneja S et al (2018) MRI-ultrasound fusion targeted biopsy of prostate imaging reporting and data system version 2 category 5 lesions found false-positive at multiparametric prostate MRI. AJR Am J Roentgenol 210:W218–W225PubMedCrossRefGoogle Scholar
  36. 36.
    Sheridan AD, Nath SK, Syed JS et al (2018) Risk of clinically significant prostate cancer associated with prostate imaging reporting and data system category 3 (equivocal) lesions identified on multiparametric prostate MRI. AJR Am J Roentgenol 210:347–357PubMedCrossRefGoogle Scholar
  37. 37.
    Lu AJ, Syed JS, Nguyen KA et al (2017) Negative multiparametric magnetic resonance imaging of the prostate predicts absence of clinically significant prostate cancer on 12-core template prostate biopsy. Urology 105:118–122PubMedCrossRefGoogle Scholar
  38. 38.
    Kasivisvanathan V, Rannikko AS, Borghi M et al (2018) MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 378:1767–1777PubMedCrossRefGoogle Scholar
  39. 39.
    Syed JS, Javier-Desloges J, Tatzel S et al (2017) Current management strategy for active surveillance in prostate cancer. Curr Oncol Rep 19:11CrossRefGoogle Scholar
  40. 40.
    Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J (1995) Long-term survival among men with conservatively treated localized prostate cancer. JAMA 274:626–631PubMedCrossRefGoogle Scholar
  41. 41.
    Chodak GW, Thisted RA, Gerber GS et al (1994) Results of conservative management of clinically localized prostate cancer. N Engl J Med 330:242–248PubMedCrossRefGoogle Scholar
  42. 42.
    Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J (1996) The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 156:127–132PubMedCrossRefGoogle Scholar
  43. 43.
    Lu-Yao GL, Albertsen P, Warren J, Yao SL (1999) Effect of age and surgical approach on complications and short-term mortality after radical prostatectomy–a population-based study. Urology 54:301–307PubMedCrossRefGoogle Scholar
  44. 44.
    Eastham JA, Kattan MW, Rogers E et al (1996) Risk factors for urinary incontinence after radical prostatectomy. J Urol 156:1707–1713PubMedCrossRefGoogle Scholar
  45. 45.
    Fowler FJ Jr, Barry MJ, Lu-Yao G, Roman A, Wasson J, Wennberg JE (1993) Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988–1990 (updated June 1993). Urology 42:622–629PubMedCrossRefGoogle Scholar
  46. 46.
    Stanford JL, Feng Z, Hamilton AS et al (2000) Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the prostate cancer outcomes study. JAMA 283:354–360PubMedCrossRefGoogle Scholar
  47. 47.
    Quinlan DM, Epstein JI, Carter BS, Walsh PC (1991) Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles. J Urol 145:998–1002PubMedCrossRefGoogle Scholar
  48. 48.
    Bill-Axelson A, Holmberg L, Filen F et al (2008) Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 100:1144–1154PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Thompson IM, Tangen CM, Paradelo J et al (2009) Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term follow-up of a randomized clinical trial. J Urol 181:956–962PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Wiegel T, Bottke D, Steiner U et al (2009) Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 27:2924–2930PubMedCrossRefGoogle Scholar
  51. 51.
    Pinkawa M, Gagel B, Piroth MD, Fischedick K et al (2009) Erectile dysfunction after external beam radiotherapy for prostate cancer. Eur Urol 55:227PubMedCrossRefGoogle Scholar
  52. 52.
    Sun M, Sammon JD, Becker A, Roghmann F et al (2014) Radical prostatectomy vs radiotherapy vs observation among older patients with clinically localized prostate cancer: a comparative effectiveness evaluation. BJU Int 113:200PubMedCrossRefGoogle Scholar
  53. 53.
    Flocks RH, Nelson CM, Boatman DL (1972) Perineal cryosurgery for prostatic carcinoma. J Urol 108:933PubMedCrossRefGoogle Scholar
  54. 54.
    Cohen JK, Miller RJ Jr, Ahmed S, Lotz MJ, Baust J (2008) Ten-year biochemical disease control for patients with prostate cancer treated with cryosurgery as primary therapy. Urology 71:515PubMedCrossRefGoogle Scholar
  55. 55.
    Chaussy CG, Thuroff S (2017) High-intensity focused ultrasound for the treatment of prostate cancer: a review. J Endourol 31:S-30CrossRefGoogle Scholar
  56. 56.
    Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR (2008) Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer 112:307PubMedCrossRefGoogle Scholar
  57. 57.
    Dechet CB, Sebo T, Farrow G, Blute ML, Engen DE, Zincke H (1999) Prospective analysis of intraoperative frozen needle biopsy of solid renal masses in adults. J Urol 162:1282–1284; discussion 4–5PubMedCrossRefGoogle Scholar
  58. 58.
    Sivalingam S, Nakada SY (2013) Contemporary minimally invasive treatment options for renal angiomyolipomas. Curr Urol Rep 14:147PubMedCrossRefGoogle Scholar
  59. 59.
    Yamakado K, Tanaka N, Nakagawa T, Kobayashi S, Yanagawa M, Takeda K (2002) Renal angiomyolipoma: relationships between tumor size, aneurysm formation, and rupture. Radiology 225:78PubMedCrossRefGoogle Scholar
  60. 60.
    Dhote R, Thiounn N, Debre B, Vidal-Trecan G (2004) Risk factors for adult renal cell carcinoma. Urol Clin North Am 31(2):237–247PubMedCrossRefGoogle Scholar
  61. 61.
    Zambrano NR, Lubensky IA, Merino MJ, Linehan WM, Walther MM (1999) Histopathology and molecular genetics of renal tumors toward unification of a classification system. J Urol 162(4):1246–1258PubMedCrossRefGoogle Scholar
  62. 62.
    Gnarra JR, Tory K, Weng Y, Schmidt L et al (1994) Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7(1):85–90PubMedCrossRefGoogle Scholar
  63. 63.
    Bosniak MA (1995) Observation of small incidentally detected renal masses. Semin Urol Oncol 13(4):267–272PubMedGoogle Scholar
  64. 64.
    Thrasher JB, Paulson DF (1993) Prognostic factors in renal cancer. Urol Clin North Am 20(2):247–262PubMedGoogle Scholar
  65. 65.
    Jayson M, Sanders H (1998) Increased incidence of serendipitously discovered renal cell carcinoma. Urology 51(2):203–205PubMedCrossRefGoogle Scholar
  66. 66.
    Ritchie AW, Chisholm GD (1983) The natural history of renal carcinoma. Semin Oncol 10(4):390–400PubMedGoogle Scholar
  67. 67.
    Syed JS, Nguyen KA, Holford TR, Hofmann JN, Shuch B (2019) Risk factors for metachronous bilateral renal cell carcinoma: a surveillance, epidemiology, and end results analysis. Cancer 15:125(2):232–238CrossRefGoogle Scholar
  68. 68.
    Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr (1999) Rising incidence of renal cell cancer in the United States. JAMA 281(17):1628–1631PubMedCrossRefGoogle Scholar
  69. 69.
    Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H (2003) Solid renal tumors: an analysis of pathological features related to tumor size. J Urol 170(6 Pt 1):2217–2220PubMedCrossRefGoogle Scholar
  70. 70.
    Syed JS, Nawaf CB, Rosoff J, Bryson C et al (2017) Adverse pathologic characteristics in the small renal mass: implications for active surveillance. Can J Urol 24(2):8759–8764PubMedGoogle Scholar
  71. 71.
    Syed JS, Lebacle C, Shuch B (2019) Barriers to pre-treatment genomic characterization of the small renal mass. Oncotarget 10(18):1667–1668PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Washburn ZW, Dillman JR, Cohan RH, Caoili EM, Ellis JH (2009) Computed tomographic urography update: an evolving urinary tract imaging modality. Semin Ultrasound CT MR 30(4):233–245PubMedCrossRefGoogle Scholar
  73. 73.
    Mulholland SG, Stefanelli JL (1990) Genitourinary cancer in the elderly. Am J Kidney Dis 16(4):324–328PubMedCrossRefGoogle Scholar
  74. 74.
    Bosniak MA (1997) The use of the Bosniak classification system for renal cysts and cystic tumors J Urol 157(5):1852–1853PubMedCrossRefGoogle Scholar
  75. 75.
    Davidson AJ, Hartman DS, Choyke PL, Wagner BJ (1997) Radiologic assessment of renal masses: implications for patient care. Radiology 202(2):297–305PubMedCrossRefGoogle Scholar
  76. 76.
    Grobner T (2006) Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21(4):1104–1108PubMedCrossRefGoogle Scholar
  77. 77.
    Blom JH, van Poppel H, Marechal JM, Jacqmin D et al (2009) Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol. 55(1):28–34PubMedCrossRefGoogle Scholar
  78. 78.
    Crispen PL, Breau RH, Allmer C, Lohse CM et al (2011) Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates. Eur Urol 59(1):18–23PubMedCrossRefGoogle Scholar
  79. 79.
    Meraney AM, Gill IS (2002) Financial analysis of open versus laparoscopic radical nephrectomy and nephroureterectomy. J Urol 167(4):1757–1762PubMedCrossRefGoogle Scholar
  80. 80.
    Eden CG, Haigh AC, Carter PG, Coptcoat MJ (1994) Laparoscopic nephrectomy results in better postoperative pulmonary function. J Endourol 8(6):419–422PubMedCrossRefGoogle Scholar
  81. 81.
    Najarian JS, Chavers BM, McHugh LE, Matas AJ (1992) 20 years or more of follow-up of living kidney donors. Lancet 340(8823):807–810PubMedCrossRefGoogle Scholar
  82. 82.
    Huang WC, Levey AS, Serio AM, Snyder M et al (2006) Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 7(9):735–740PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Castilla EA, Liou LS, Abrahams NA, Fergany A et al (2002) Prognostic importance of resection margin width after nephron-sparing surgery for renal cell carcinoma. Urology 60(6):993–997PubMedCrossRefGoogle Scholar
  84. 84.
    Becker A, Ravi P, Roghmann F et al (2014) Laparoscopic radical nephrectomy vs laparoscopic or open partial nephrectomy for T1 renal cell carcinoma: comparison of complication rates in elderly patients during the initial phase of adoption. Urology 83(6):1285–1291PubMedCrossRefGoogle Scholar
  85. 85.
    Balducci L (2009) Supportive care in elderly cancer patients. Curr Opin Oncol 21(4):310–317PubMedCrossRefGoogle Scholar
  86. 86.
    Motzer RJ, Escudier B, Oudard S, Hutson TE et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449–456PubMedCrossRefGoogle Scholar
  87. 87.
    Gore ME, Szczylik C, Porta C, Bracarda S et al (2009) Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 10(8):757–763PubMedCrossRefGoogle Scholar
  88. 88.
    Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10–29PubMedCrossRefGoogle Scholar
  89. 89.
    Prout GR Jr, Wesley MN, Yancik R, Ries LAG, Havlik RJ, Edwards BK (2005) Age and comorbidity impact surgical therapy in older bladder carcinoma patients: a population-based study. Cancer 104(8):1638–1647PubMedCrossRefGoogle Scholar
  90. 90.
    Mariani AJ, Mariani MC, Macchioni C, Stams UK, Hariharan A, Moriera A (1989) The significance of adult hematuria: 1,000 hematuria evaluations including a risk-benefit and cost-effectiveness analysis. J Urol 141(2):350–355PubMedCrossRefGoogle Scholar
  91. 91.
    Ro JY, Staerkel GA, Ayala AG (1992) Cytologic and histologic features of superficial bladder cancer. Urol Clin North Am 19(3):435–453PubMedGoogle Scholar
  92. 92.
    Allard P, Bernard P, Fradet Y, Tetu B (1998) The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index. Br J Urol 81(5):692–698PubMedCrossRefGoogle Scholar
  93. 93.
    Droller MJ (1992) Treatment of regionally advanced bladder cancer. An overview. Urol Clin North Am 19(4):685–693PubMedGoogle Scholar
  94. 94.
    Thrasher JB, Crawford ED (1993) Current management of invasive and metastatic transitional cell carcinoma of the bladder. J Urol 149(5):957–972PubMedCrossRefGoogle Scholar
  95. 95.
    Fitzpatrick JM, West AB, Butler MR, Lane V, O’Flynn JD (1986) Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection. J Urol 135(5):920–922PubMedCrossRefGoogle Scholar
  96. 96.
    Holmang S, Hedelin H, Anderstrom C, Johansson SL (1995) The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol 153(6):1823–1826; discussion 1826–1827PubMedCrossRefGoogle Scholar
  97. 97.
    Prout GR Jr, Wesley MN, Yancik R, Ries LAG, Havlik RJ, Edwards BK (1987) The outcome of conservative treatment of carcinoma in situ of the bladder. J Urol 138(4):766–770PubMedCrossRefGoogle Scholar
  98. 98.
    Peyromaure M, Zerbib M (2004) T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival. BJU Int 93(1):60–63PubMedCrossRefGoogle Scholar
  99. 99.
    Soloway MS, Sofer M, Vaidya A (2002) Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol 167(4):1573–1583PubMedCrossRefGoogle Scholar
  100. 100.
    Esrig D, Freeman JA, Stein JP, Skinner DG (1997) Early cystectomy for clinical stage T1 transitional cell carcinoma of the bladder. Semin Urol Oncol 15(3):154–160PubMedGoogle Scholar
  101. 101.
    Sylvester RJ, Oosterlinck W, Holmang S et al (2016) Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa–pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation? Eur Urol 69:231–244PubMedCrossRefGoogle Scholar
  102. 102.
    Chang SS, Bochner BH, Chou R et al (2017) Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline. J Urol 198(3):552–559PubMedPubMedCentralCrossRefGoogle Scholar
  103. 103.
    Chamie K, Hu B, Devere White RW, Ellison LM (2008) Cystectomy in the elderly: does the survival benefit in younger patients translate to the octogenarians? BJU Int 102(3):284–290PubMedCrossRefGoogle Scholar
  104. 104.
    Nielsen ME, Shariat SF, Karakiewicz PI, Lotan Y et al (2007) Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. Eur Urol 51(3):699–706PubMedCrossRefGoogle Scholar
  105. 105.
    Weizer AZ, Joshi D, Daignault S, Kinnaman M et al (2007) Performance status is a predictor of overall survival of elderly patients with muscle invasive bladder cancer. J Urol 177(4):1287–1293PubMedCrossRefGoogle Scholar
  106. 106.
    Roehrborn CG, Sagalowsky AI, Peters PC (1991) Long-term patient survival after cystectomy for regional metastatic transitional cell carcinoma of the bladder. J Urol 146(1):36–39PubMedCrossRefGoogle Scholar
  107. 107.
    Sternberg CN (1995) The treatment of advanced bladder cancer. Ann Oncol 6(2):113–126PubMedCrossRefGoogle Scholar
  108. 108.
    von der Maase H, Hansen SW, Roberts JT et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068–3077PubMedCrossRefGoogle Scholar
  109. 109.
    Bamias A, Efstathiou E, Moulopoulos LA, Gika D et al (2005) The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy. Ann Oncol 16(2):307–313PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of UrologyYale University School of MedicineNew HavenUSA

Section editors and affiliations

  • Jason Johanning
    • 1
  • Sandhya Lagoo-Deenadayalan
    • 2
  1. 1.Department of SurgeryUniversity of Nebraska Medical CenterOmahaUSA
  2. 2.Duke MedicineDurhamUSA

Personalised recommendations